Connexion
E-mail
Mot de passe
Afficher le mot de passe
Retenir
Mot de passe oublié ?
Devenir membre gratuitement
Inscription
Inscription
Devenir membre
Inscription gratuite
Devenir client
Découvrez nos services
Paramètres
Paramètres
Cotations dynamiques 
OFFON

PROTAGONIST THERAPEUTICS, INC.

(PTGX)
  Rapport
SynthèseCotationsGraphiquesActualitésNotationsAgendaSociétéFinancesConsensusRévisionsDérivésFondsCommunauté 
SynthèseToute l'actualitéReco analystesAutres languesCommuniquésPublications officiellesActualités du secteur
Actualités dans d'autres langues sur PROTAGONIST THERAPEUTICS, INC.
04/01/C O R R E C T I O N -- Protagonist Therapeutics, Inc./
2021INSIDER SELL : Protagonist Therapeutics
2021Protagonist Therapeutics Presents Updated Phase 2 Rusfertide Data
2021Protagonist Therapeutics to Present at the JMP Securities Hematology and Oncology Summi..
2021Protagonist Therapeutics Picks PN-235 for Mid-Stage Trials in Multiple Indications
2021Protagonist Therapeutics Announces the Selection of Oral Peptide PN-235 into Phase 2 Cl..
2021Protagonist Therapeutics Announces Selection of Oral Peptide PN-235 into Phase 2 Clinic..
2021Protagonist Therapeutics Announces Positive Phase 2a Data Supporting the Potential Use ..
2021Protagonist Therapeutics Announces 'Positive Data' for Rusfertide as Possible Hereditar..
2021Protagonist Therapeutics, Inc. Announces Positive Phase 2A Data Supporting the Potentia..
2021Protagonist Therapeutics to Participate in Two Upcoming Healthcare Investor Conferences
2021Protagonist Therapeutics Announces Updated Data from Phase 2 Study of Rusfertide in Pol..
2021PROTAGONIST THERAPEUTICS : Q3 Earnings Snapshot
2021PROTAGONIST THERAPEUTICS, INC MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDIT..
2021Protagonist Therapeutics Reports Third Quarter 2021 Financial Results and Provides Corp..
2021Protagonist Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine ..
2021Protagonist Therapeutics Gets $7.5 Million Milestone Payment from Johnson & Johnson's J..
2021Protagonist Therapeutics Earns $7.5 Million Milestone Payment from IL-23 Receptor Colla..
2021Protagonist Therapeutics Earns $7.5 Million Milestone Payment from IL-23 Receptor Colla..
2021NORTH AMERICAN MORNING BRIEFING : Stock Futures -3-
2021PROTAGONIST THERAPEUTICS : Shares Drop on Elevated Volume
2021It's just a period of market normalization
2021PROTAGONIST THERAPEUTICS : to Present at the Jefferies Next Generation IBD Therapeutics Su..
2021ANALYST RECOMMENDATIONS : Cigna, Halliburton, Nike, Nio, Trex...
2021Health Care Stocks Sliding in Late Monday Trading
2021Health Care Stocks Drifting Monday as Biotechs Climb
2021Top Midday Gainers
2021Health Care Stocks Trade Lower Premarket Monday
2021Wall Street Declines on Soaring Energy Prices
2021PROTAGONIST THERAPEUTICS : Health Care
2021PROTAGONIST THERAPEUTICS : Says FDA Lifts Clinical Hold on Rusfertide Trials; Shares Surge..
2021Top Premarket Gainers
2021PROTAGONIST THERAPEUTICS : Announces Removal of FDA Clinical Hold on the Rusfertide Clinic..
2021Protagonist Therapeutics Announces Removal of Fda Clinical Hold on the Rusfertide Clini..
2021Protagonist Therapeutics' Clinical Hold on Rusfertide Lifted
2021PROTAGONIST THERAPEUTICS : Announces Data from Phase 2 Rusfertide Study in Hereditary Hemo..
2021ANNEXON : Names Larry Mattheakis as Chief Scientific Officer
2021PROTAGONIST ALERT : Bragar Eagel & Squire, P.C. is Investigating Protagonist on Behalf of ..
2021Top Midday Decliners
2021PROTAGONIST THERAPEUTICS : Reports FDA Clinical Hold on Rusfertide Clinical Development Pr..
2021PROTAGONIST THERAPEUTICS' : Clinical Studies of Rusfertide Placed on Hold by FDA -- Shares..
2021PROTAGONIST THERAPEUTICS : Reports FDA Clinical Hold on Rusfertide Clinical Development Pr..
2021PROTAGONIST THERAPEUTICS, INC : Other Events, Financial Statements and Exhibits (form 8-K)
2021NASDAQ 100 : Top Midday Decliners
2021Wall Street Futures in Holding Pattern Ahead of Fed Meeting Next Week
2021Health Care Stocks Mixed Premarket Friday
2021PROTAGONIST THERAPEUTICS : Health Care
2021Protagonist Therapeutics Shares Tumble as FDA Puts Rusfertide on Hold
2021Top Premarket Decliners
2021PROTAGONIST THERAPEUTICS' : Clinical Studies of Rusfertide Placed on Hold by FDA; Shares F..
2021PROTAGONIST THERAPEUTICS : Reports FDA Clinical Hold on Rusfertide Clinical Development Pr..
2021Protagonist Therapeutics Reports FDA Clinical Hold on Rusfertide Clinical Development P..
2021Protagonist Drug Studies Placed on FDA Hold
2021PROTAGONIST THERAPEUTICS : Reports Granting of Inducement Awards
2021PROTAGONIST THERAPEUTICS : Appoints Scott Plevy, M.D., Executive Vice President and Therap..
2021Protagonist Therapeutics Appoints Scott Plevy, M.D., Executive Vice President and Thera..
2021Certain Warrants of Protagonist Therapeutics, Inc. are subject to a Lock-Up Agreement E..
2021Certain Common Stock of Protagonist Therapeutics, Inc. are subject to a Lock-Up Agreeme..
2021Certain Options of Protagonist Therapeutics, Inc. are subject to a Lock-Up Agreement En..
2021PROTAGONIST THERAPEUTICS : Resolves Contract Dispute With Zealand Pharma
2021PROTAGONIST THERAPEUTICS : Announces Resolution of Contract Dispute with Zealand Pharma
2021PROTAGONIST THERAPEUTICS, INC : Entry into a Material Definitive Agreement (form 8-K)
2021PROTAGONIST THERAPEUTICS : Q2 Earnings Snapshot
2021PROTAGONIST THERAPEUTICS : Reports Second Quarter 2021 Financial Results and Recent Compan..
2021PROTAGONIST THERAPEUTICS : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND..
2021Protagonist Therapeutics, Inc. Reports Earnings Results for the Second Quarter Ended Ju..
2021PROTAGONIST THERAPEUTICS : Reports Second Quarter 2021 Financial Results and Recent Compan..
2021PROTAGONIST THERAPEUTICS, INC : Entry into a Material Definitive Agreement (form 8-K)
2021PROTAGONIST THERAPEUTICS : Announces Amendment of Agreement with Janssen Biotech for the C..
2021Protagonist Therapeutics, Inc. Announces Amendment of Agreement with Janssen Biotech, I..
2021PROTAGONIST THERAPEUTICS : Reports Granting of Inducement Award
2021PROTAGONIST THERAPEUTICS INC. : Announces Closing of $132.2 Million Public Offering of Com..
2021PROTAGONIST THERAPEUTICS' : Underwriters Exercise Overallotment Options, Boosting Public O..
2021PROTAGONIST THERAPEUTICS, INC. : Announces Closing of $132.2 Million Public Offering of Co..
2021PROTAGONIST THERAPEUTICS, INC : Other Events, Financial Statements and Exhibits (form 8-K)
1  2  3  4  5Suiv.
Prochain événement sur PROTAGONIST THERAPEUTICS, INC.